2014

Catalent, Valerion collaborate on orphan genetic disorder treatments

Thursday, December 4, 2014

Catalent Pharma Solutions, a Somerset, N.J.-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is collaborating with Valerion Therapeutics, a Concord, Mass.-based emerging science-driven company focused on the development of bio-therapeutics for orphan genetic diseases, to develop Valerion’s two lead product candidates.

[Read More]

Diagnostics Development Hub to boost biomedical research in Singapore

Thursday, December 4, 2014

Singapore’s biomedical research sector received a major boost with the launch of a new Diagnostics Development (DxD) Hub. The DxD Hub aims to develop medical diagnostics as one part of the medical technologies industry, improve healthcare through development of diagnostic solutions and accelerate production of new diagnostics devices. Diagnostics is one of four innovation clusters shortlisted to be funded under the $200 million Innovation Cluster Program (ICP) launched Oct. 2013.

[Read More]

Foundation Medicine, Flatiron Health collaborate to develop data platform

Wednesday, December 3, 2014

Foundation Medicine, a molecular information company based in Cambridge, Mass., and Flatiron Health, a healthcare technology company headquartered in New York, have announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.

[Read More]

Report: Global stem cell market to reach $118B by 2018

Wednesday, December 3, 2014

The global stem cell market earned revenues of $40.01 billion in 2013 and is estimated to nearly triple to $117.66 billion in 2018 at a compound annual growth rate (CAGR) of 24.1%, according to a new analysis from Frost & Sullivan. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, Asia-Pacific is expected to record the highest CAGR during the forecast period. In fact, the APAC stem cell market, which was valued at $5.6 billion in 2013, is projected to increase to $18.71 billion by 2018.

[Read More]

Edison Nation Medical, Mount Sinai Health System collaborate

Wednesday, December 3, 2014

Edison Nation Medical, a marketplace for healthcare and medical device innovation headquartered in Charlotte, N.C., has partnered with Mount Sinai Health System, a New York-based integrated healthcare network providing medical care and medical research. Edison Nation Medical will work closely with Mount Sinai Innovation Partners (MSIP), Mount Sinai’s technology development and commercialization group, to prioritize and bring to market medical device and consumer related healthcare inventions from the Mount Sinai community.

[Read More]

Zosano Pharma, Eli Lilly to develop osteoporosis treatment

Wednesday, December 3, 2014

Zosano Pharma, based in Fremont, Calif., and Eli Lilly have entered into an exclusive agreement to develop ZP-PTH, Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) using Zosano’s microneedle patch system for treating osteoporosis patients, globally. Zosano has completed a phase II study of ZP-PTH for the treatment of severe osteoporosis and plans to conduct phase III development.

[Read More]